As hedge funds hurriedly file their second quarter stock holdings with the Securities and Exchange Commission ahead of Monday’s deadline, observers are no doubt very interested in seeing who bought, sold or held onto their shares of Valeant Pharmaceuticals International, the controversial drug maker whose share price plunged more than 90 percent in a year amid revelations...
